L-carnitine Ameliorated Fasting-induced Fatigue, Hunger, And Metabolic Abnormalities In Patients With Metabolic Syndrome: A Randomized Controlled Study
Notes for this study:
||mg/l Mean and SD. Placebo: before 1.11 ± 0.24, after 0.93 ± 0.17. Carnitine: before 1.32 ± 0.19, after 1.16 ± 0.17.
|Number of Subjects
In this randomized, single-blind, placebo-controlled pilot trial, 30 participants with metabolic syndrome took for 7 days.
The primary outcome was weight loss, and there was a statistically significant greater reduction in body mass and waist circumference, but not hip circumference. There was also a statistically significant reduction in total cholesterol, but not any other lipid measure. There was a statistically significant greater reduction in fasting insulin and GGT but not fasting glucose, insulin resistance, c-reactive protein, uric acid, free fatty acids, AST, or ALT, though many were close. The carnitine group perceived less hunger and reported less fatigue.